These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15746079)

  • 21. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
    Liao AT; Chien MB; Shenoy N; Mendel DB; McMahon G; Cherrington JM; London CA
    Blood; 2002 Jul; 100(2):585-93. PubMed ID: 12091352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.
    Da Silva Figueiredo Celestino Gomes P; Panel N; Laine E; Pascutti PG; Solary E; Tchertanov L
    PLoS One; 2014; 9(5):e97519. PubMed ID: 24828813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.
    Chaix A; Arcangeli ML; Lopez S; Voisset E; Yang Y; Vita M; Letard S; Audebert S; Finetti P; Birnbaum D; Bertucci F; Aurrand-Lions M; Dubreuil P; De Sepulveda P
    Oncogene; 2014 Feb; 33(7):872-81. PubMed ID: 23416972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.
    Gebreyohannes YK; Burton EA; Wozniak A; Matusow B; Habets G; Wellens J; Cornillie J; Lin J; Nespi M; Wu G; Zhang C; Bollag G; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Exp Med; 2019 May; 19(2):201-210. PubMed ID: 30523507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signal transduction by several KIT juxtamembrane domain mutations.
    Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
    Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.
    Le Gall M; Crépin R; Neiveyans M; Auclair C; Fan Y; Zhou Y; Marks JD; Pèlegrin A; Poul MA
    Mol Cancer Ther; 2015 Nov; 14(11):2595-605. PubMed ID: 26358753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.
    Chen H; Isozaki K; Kinoshita K; Ohashi A; Shinomura Y; Matsuzawa Y; Kitamura Y; Hirota S
    Int J Cancer; 2003 May; 105(1):130-5. PubMed ID: 12672043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment.
    Bougherara H; Subra F; Crépin R; Tauc P; Auclair C; Poul MA
    Mol Cancer Res; 2009 Sep; 7(9):1525-33. PubMed ID: 19737976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KIT mutations in mastocytosis and their potential as therapeutic targets.
    Gotlib J
    Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in signaling pathways and expression level of the phosphoinositide phosphatase SHIP1 between two oncogenic mutants of the receptor tyrosine kinase KIT.
    Vanderwinden JM; Wang D; Paternotte N; Mignon S; Isozaki K; Erneux C
    Cell Signal; 2006 May; 18(5):661-9. PubMed ID: 15990278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.
    Spiekermann K; Faber F; Voswinckel R; Hiddemann W
    Exp Hematol; 2002 Jul; 30(7):767-73. PubMed ID: 12135675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
    Guida T; Anaganti S; Provitera L; Gedrich R; Sullivan E; Wilhelm SM; Santoro M; Carlomagno F
    Clin Cancer Res; 2007 Jun; 13(11):3363-9. PubMed ID: 17545544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation.
    Hashimoto K; Matsumura I; Tsujimura T; Kim DK; Ogihara H; Ikeda H; Ueda S; Mizuki M; Sugahara H; Shibayama H; Kitamura Y; Kanakura Y
    Blood; 2003 Feb; 101(3):1094-102. PubMed ID: 12393643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells.
    Hara Y; Obata Y; Horikawa K; Tasaki Y; Suzuki K; Murata T; Shiina I; Abe R
    PLoS One; 2017; 12(4):e0175514. PubMed ID: 28403213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.